Status:
UNKNOWN
Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas.
Lead Sponsor:
Post Graduate Institute of Medical Education and Research, Chandigarh
Conditions:
Macroprolactinoma
Eligibility:
All Genders
Phase:
NA
Brief Summary
To study the effects of rapid escalation of Cabergoline in comparison to conventional dosing in macroprolactinomas. Rapid escalation of cabergoline may help in earlier normalization of prolactin and s...
Detailed Description
The efficacy of cabergoline is dose related and determined by percentage of Dopamine 2 receptor occupancy and prolonged receptor affinity. Activation of membrane receptors and target cell responses is...
Eligibility Criteria
Inclusion
- Males or females presenting with
- Prolactin secreting macroadenomas (≥10 mm maximum diameter)
- With/without visual complaints
- With /without parasellar or suprasellar extension
- Treatment Naïve
Exclusion
- On treatment with dopamine agonists.
- Taking other drugs influencing prolactin Levels.
- Systemic disease like Chronic Kidney Disease, Chronic Lung Disease
- Other secondary causes of hyperprolactinemia.
- Prolactin secreting microadenomas
- Pregnancy during follow up
- Prolactinoma as part of MEN-1 Syndrome
- History suggestive of recent apoplexy (3 months)
- Contraindication to cabergoline therapy like pre existing psychosis.
Key Trial Info
Start Date :
May 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2012
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01143584
Start Date
May 1 2010
End Date
March 1 2012
Last Update
June 14 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Postgraduate Institute of Medical Education and Research
Chandigarh, Chandigarh, India, 1700112